Categories Earnings, Health Care

CorMedix, Inc. (NYSE: CRMD): Q3 2019 Earnings Snapshot

— CorMedix, Inc. (NYSE: CRMD) reported a net loss attributable to common shareholders of $32.4 million or $1.35 per share for the third quarter, compared to a loss of $10.2 million or $0.54 per share last year. Analysts estimated a loss of $0.25 per share

— Net sales dropped to $59 thousand from $372 thousand in the same period of last year, vs. $190 thousand expected

— Net loss before recognition of the deemed dividends was $5.3 million

— Operating expenses were $5.2 million in Q3, compared with $10.3 million in the third quarter of 2018

— Completed interaction with the FDA, related to the chemistry and manufacturing package required to support the NDA for Neutrolin

— In September, closed an exchange agreement with funds managed by Elliott Management Corporation, CorMedix’s largest investor

Listen to publicly listed companies’ earnings conference calls along with the edited closed caption text

Most Popular

What to look for when CVS Health (CVS) reports Q3 earnings

Healthcare company CVS Health Corporation (NYSE: CVS) is all set to report earnings next week, with Wall Street expecting a mixed outcome. The company has been facing challenges in certain

eBay (EBAY): A few factors that helped drive growth in Q3 2024

Shares of eBay Inc. (NASDAQ: EBAY) stayed green on Friday. The stock has gained 32% year-to-date. The ecommerce leader delivered revenue and earnings growth for the third quarter of 2024,

CVX Earnings: Chevron reports lower revenue and profit for Q3 2024

Energy exploration company Chevron Corporation (NYSE: CVX) on Friday announced third-quarter 2024 financial results, reporting a decline in net profit and revenues. Net income attributable to Chevron Corporation dropped to

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top